AKERS BIOSCIENCES

Akers Biosciences develops, manufactures, and supplies rapid, point-of-care screening and testing products that deliver health-related information directly to individuals or their treating clinicians. Their core strength is rooted in six proprietary platform technologies that merge diagnostic accuracy with maximum portability and ease of use. Their objective is to apply these flexible platforms to the development of rapid tests that fulfill unmet needs in a variety of fields including cardiology/emergency medicine, infectious disease, metabolism/nutrition, neuropsychiatry, oncology, as well as on- and off-the-job alcohol safety. Aker Bioscience is acquired by MyMD Pharmaceuticals in a reverse merger.